Patents for A61P 35 - Antineoplastic agents (221,099)
09/1999
09/08/1999EP0939805A2 Secreted proteins and polynucleotides encoding them
09/08/1999EP0939765A1 Glycoconjugates of modified camptothecin derivatives (a- or b-ring linkage)
09/08/1999EP0939757A1 Novel integrin receptor antagonists
09/08/1999EP0939654A1 Association of no syntase inhibitors with trappers of oxygen reactive forms
09/08/1999EP0939653A1 Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
09/08/1999EP0939650A1 Vaccines
09/08/1999EP0939645A1 Cancer therapy using an oncogene product and a foreign mhc molecule
09/08/1999EP0939640A1 Improvements in polymer compositions for chemotherapy and methods of treatment using the same
09/08/1999EP0939627A1 Pentafluorobenzenesulfonamides and analogs
09/08/1999EP0939621A1 Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
09/08/1999EP0749415B1 Benzamide analogs, useful as parp (adp-ribosyltransferase, adprt) dna repair enzyme inhibitors
09/08/1999CN1228091A Substituted 6,6-hetero-bicyclic derivatives
09/08/1999CN1228090A Naphthyridines with affect IL-4 and G-CSF
09/08/1999CN1228088A Arylsulfonylimidazolone derivatives as antimumor agent
09/08/1999CN1228083A Arylsulfonylamino hydroxamic acid derivatives
09/08/1999CN1228028A Use of histamine for therapeutic purposes
09/08/1999CN1227871A Nuclein structural body for gene treating method
09/07/1999US5948902 Antisense oligonucleotides to human serine/threonine protein phosphatase genes
09/07/1999US5948901 Antisense oligonucleotides for aromatase inhibition
09/07/1999US5948898 Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
09/07/1999US5948896 Processes for preparing 13-deoxy anthracycline derivatives
09/07/1999US5948809 (-) cis-6(S)-phenyl-5(R) 4-(2-pyrrolidin-1-yl ethoxy) phenyl!-5,6,7,8-tetrahydronaphthalen-2-ol-D-tartrate
09/07/1999US5948796 Benzo B!thiophene compounds, intermediates, formulations, and methods
09/07/1999US5948795 Benzothiopene compounds, and uses and formulations thereof
09/07/1999US5948767 Transport of active material into cells; drug delivery
09/07/1999US5948675 Host-vector system which can be used in gene therapy
09/07/1999US5948669 As probes and primers; for diagnosis and treatment of osteoporosis, oral diseases, paget's disease; antiarthritic agents, anticarcinogenic/antitumor/antimetastasis agents
09/07/1999US5948647 Nucleic acids encoding antigen-binding sites specific for cancer antigens
09/07/1999US5948642 Polynucleotide from staphylococcus aureus which codes for resolvase polypeptide; for diagnosis of infections; as bactericides; for screening for novel antibiotics; treatment of toxic shock syndrome
09/07/1999US5948640 Mammalian additional sex combs (mammalian Asx) acts as a tumor suppressor
09/07/1999US5948402 Method of using IL-11 for treating antibiotic induced diarrhea
09/07/1999CA2167257C Use of sertraline to treat cancer patients
09/07/1999CA2006119C Anti-aids viral agents and anticancer action
09/04/1999CA2231005A1 Cyclin dependent kinase inhibitor
09/02/1999WO1999043832A2 Human proteinase molecules
09/02/1999WO1999043829A2 Cell cycle related proteins
09/02/1999WO1999043817A1 High affinity humanized anti-cea monoclonal antibodies
09/02/1999WO1999043816A1 High affinity humanized anti-tag-72 monoclonal antibodies
09/02/1999WO1999043814A1 Therapeutic blockade of icer synthesis to prevent icer-mediated inhibition of immune cell activity
09/02/1999WO1999043807A2 Human channel-related molecules
09/02/1999WO1999043806A1 Human smn-like protein
09/02/1999WO1999043800A1 TUMOR ASSOCIATED ANTIGEN 791Tgp72
09/02/1999WO1999043698A1 Substance having steroid-like structure, process for the production thereof and antitumor agents containing the same
09/02/1999WO1999043691A1 2'-fluoronucleosides
09/02/1999WO1999043676A2 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines
09/02/1999WO1999043675A1 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines
09/02/1999WO1999043672A1 Inhibitors of phospholipase a2
09/02/1999WO1999043663A1 N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia
09/02/1999WO1999043653A1 Synthesis of epothilones, intermediates thereto and analogues therof
09/02/1999WO1999043646A1 Cyclohexanediole derivatives
09/02/1999WO1999043636A2 Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
09/02/1999WO1999043355A2 Formulations containing oxaliplatin
09/02/1999WO1999043340A1 Oral compositions at low dosage of cytotoxic proteins
09/02/1999WO1999043320A1 Use of epothilones for the treatment of cancer
09/02/1999WO1999043314A1 Farnesyl-protein transferase inhibitors
09/02/1999WO1999043310A2 20-hete antagonists and agonists
09/02/1999WO1999043286A2 Isolated stromal cells for use in the treatment of diseases of the central nervous system
09/02/1999WO1999043217A1 Use of d-tagatose as a prebiotic food component
09/02/1999WO1999043208A1 The helios gene
09/02/1999WO1999033488A3 Adjuvanted vaccine formulation
09/02/1999WO1999030720A8 Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha
09/02/1999WO1999024460A3 Dipeptide nitriles
09/02/1999WO1999023105A9 Vegi, an inhibitor of angiogenesis and tumor growth
09/02/1999WO1999002711A3 Fusion proteins with an immunoglobulin hinge region linker
09/02/1999WO1998040052A9 Cationic lipid compositions targeting angiogenic endothelial cells
09/02/1999WO1998030693A9 Tumor necrosis factor receptor 5
09/02/1999CA2322163A1 Inhibitors of phospholipase a2
09/02/1999CA2321993A1 Therapeutic blockade of icer synthesis to prevent icer-mediated inhibition of immune cell activity
09/02/1999CA2321974A1 Tumor associated antigen 791tgp72
09/02/1999CA2321947A1 High affinity humanized anti-cea monoclonal antibodies
09/02/1999CA2321932A1 High affinity humanized anti-tag-72 monoclonal antibodies
09/02/1999CA2321883A1 Isolated stromal cells for use in the treatment of diseases of the central nervous system
09/02/1999CA2321870A1 Cell cycle related proteins
09/02/1999CA2321869A1 Human proteinase molecules
09/02/1999CA2321747A1 Human smn-like protein
09/02/1999CA2321719A1 Farnesyl-protein transferase inhibitors
09/02/1999CA2321717A1 Oral compositions at low dosage of cytotoxic proteins
09/02/1999CA2321667A1 Human channel-related molecules
09/02/1999CA2321642A1 N-¬(substituted five-membered di- or triaza diunsaturated ring)carbonyl|guanidine derivatives for the treatment of ischemia
09/02/1999CA2321528A1 Substance having steroid-like structure, method for preparation therof and antitumor agent containing
09/02/1999CA2321307A1 Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
09/02/1999CA2319752A1 Use of epothilones for the treatment of cancer
09/01/1999EP0939131A2 Aminopeptidases
09/01/1999EP0939124A2 MGBP1 sequences
09/01/1999EP0939123A2 Estrogen receptor-related polypetide SBPERR4
09/01/1999EP0939082A1 Protein polysaccharide 0041
09/01/1999EP0938554A1 Human protein kinase c inhibitor homolog
09/01/1999EP0938547A1 Modified ligands of calcium-dependent binding proteins
09/01/1999EP0938505A1 Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
09/01/1999EP0938500A1 INTERLEUKIN-1beta-CONVERTING ENZYME (ICE) INHIBITING PEPTIDES
09/01/1999EP0938498A1 Multivalent compounds for cross-linking receptors and uses thereof
09/01/1999EP0938496A1 Heptapeptide oxytocin analogues
09/01/1999EP0938494A1 Inhibitors of protein farnesyl transferase
09/01/1999EP0938486A1 Substituted pyrrolopyrimidines and processes for their preparation
09/01/1999EP0938477A1 Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors
09/01/1999EP0938474A2 Cyclopropylindole compounds and their use as prodrugs
09/01/1999EP0938471A1 The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
09/01/1999EP0938343A2 Tumor delivery vehicles and method to enhance treatment of cystic tumors
09/01/1999EP0938329A1 Immunogenic tlp composition
09/01/1999EP0938323A2 Treatment of highly vascular tumours